2016
DOI: 10.1161/atvbaha.115.306827
|View full text |Cite
|
Sign up to set email alerts
|

Carboxyl-Terminal Cleavage of Apolipoprotein A-I by Human Mast Cell Chymase Impairs Its Anti-Inflammatory Properties

Abstract: Supplemental Digital Content is available in the text.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
18
0

Year Published

2016
2016
2024
2024

Publication Types

Select...
9
1

Relationship

1
9

Authors

Journals

citations
Cited by 30 publications
(19 citation statements)
references
References 66 publications
1
18
0
Order By: Relevance
“…Recently, it was established that chymase cleaves ApoA-I resulting in loss of its anti-inflammatory functions [20]. Moreover, cathepsin G, another protease released from mast cells, has been reported to degrade LDL, reducing LDL-C and ApoB levels [21].…”
Section: Discussionmentioning
confidence: 99%
“…Recently, it was established that chymase cleaves ApoA-I resulting in loss of its anti-inflammatory functions [20]. Moreover, cathepsin G, another protease released from mast cells, has been reported to degrade LDL, reducing LDL-C and ApoB levels [21].…”
Section: Discussionmentioning
confidence: 99%
“…TNFα played a critical role in the promotion of atherosclerosis by decreasing cellular cholesterol efflux from foam cells [ 15 , 24 ]. Accumulated oxidative stress induced by TNFα led to the endothelial impairment and resulted in atherosclerotic lesions [ 25 26 ].…”
Section: Discussionmentioning
confidence: 99%
“…Interestingly, smokers had not only less apoA-I, but they also had fewer macrophages in their sIAs. Although smoking did not seem to affect lipid accumulation, it may inhibit the various protective functions of apoA-I, for example via activation of mast cells and subsequent release of proteases that degrade apoA-I (44), and so block its ability to induce efflux from foam cells and to act as an anti-inflammatory component in the arterial wall (45).…”
Section: Correlation With Clinical Risk Factorsmentioning
confidence: 99%